# FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss

- Section: Tech
- Newsroom score: Widely confirmed (5 of 5 newsrooms notfiction follows on this beat)
- First reported by The Guardian at 2026-11-10T13:00:53.000Z
- Last updated: 2026-11-10T14:43:49.000Z (no longer tracked live)
- notfiction page: https://notfiction.com/s/1sandlu

## What the coverage agrees on (AI summary)

- The FDA has found evidence of a potential increased risk of a rare eye condition linked to GLP-1 drugs.
- The rare eye condition can lead to vision loss or blindness.
- The FDA has ordered makers of GLP-1 drugs to add a warning about the condition to their labels.
- The drugs affected include Ozempic, Wegovy, and Zepbound.
- The risk appears small and the data is mixed, but the FDA wants patients to be aware.

## Where outlets differ

- The Guardian focuses on how the popularity of GLP-1 weight-loss drugs could divert pharmaceutical firms' attention away from basic diabetes treatments like insulin, especially in poorer countries. (The Guardian, Ars Technica, BBC News, CNBC, CBS News)
- Ars Technica emphasizes that the risk appears small and the data is mixed, while other outlets focus more on the FDA's warning and label requirements. (Ars Technica, BBC News, CNBC, CBS News)
- BBC News and CBS News explicitly name the condition as NAION, while other outlets refer to it only as a rare eye condition. (BBC News, CBS News, Ars Technica, CNBC, The Guardian)

## Reported by only one outlet

- The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms' attention away from diabetes treatments such as insulin, according to the head of the Access to Medicine Foundation. (The Guardian)

## How each outlet reported it, in order

- 2026-11-10T13:00:53.000Z — The Guardian: [Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn](https://www.theguardian.com/business/2026/nov/10/pharma-firms-weight-loss-drugs-insulin-glp-1-ozempic-mounjaro)
- 2026-11-10T14:43:49.000Z — Ars Technica: [FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss](https://arstechnica.com/health/2026/11/glp-1-drugs-may-increase-risk-of-vision-loss-from-rare-condition-fda-warns/)
- 2026-11-10T18:43:04.000Z — BBC News: [Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness](https://www.bbc.co.uk/news/articles/crwydyde0lp3o?at_medium=RSS&at_campaign=rss)
- 2026-11-10T23:03:11.000Z — CNBC: [FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound](https://www.cnbc.com/2026/11/10/fda-warning-vision-loss-glp1-wegovy-zepbound.html)
- 2026-11-11T01:59:54.000Z — CBS News: [GLP-1 drugs to carry warning about rare vision-loss side effect, FDA says](https://www.cbsnews.com/video/glp-1-drugs-to-carry-warning-about-rare-vision-loss-side-effect-fda-says/)

## Related stories

- [Watchdog says AI smart glasses may violate your privacy](https://notfiction.com/s/g7pwf9.md): Confirmed, 2 newsrooms

Source: notfiction (https://notfiction.com). Headlines belong to their publishers; link to the original reporting. The AI summary is written by notfiction’s own model and can be wrong.
